MedTrace Logo

Effect of Topical Imiquimod on Lentigo Maligna

NCT01161888 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-06-20

No results posted yet for this study

Summary

The purpose of this study is to determine if topical imiquimod is effective in the pathological complete regression of lentigo maligna.

Conditions

  • Lentigo Maligna

Interventions

DRUG

Imiquimod

250mg sachets to be applied at a start dose of 5 days a week. Dose will be adjusted using an algorithm according to tolerability.

Sponsors & Collaborators

  • Department of Health, United Kingdom

    collaborator OTHER_GOV

  • Jerry Marsden

    lead OTHER

Principal Investigators

  • Jerry Marsden, Dr · University Hospital Birmingham NHS Foundation Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01161888 on ClinicalTrials.gov